On Apr. 6, 2020, the Minneapolis Heart Institute Foundation (MHIF) announced it was serving as the international coordinating and data center for the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI) in addition to enrolling patients into the study.

This registry is a research study designed to collect data on COVID-19 positive patients or persons under investigation (suspected to have COVID-19 infection) with ST-Elevation Myocardial Infarction (STEMI), a serious heart attack involving a blockage in one of the heart’s major arteries that supplies oxygen and nutrient-rich blood to the heart muscle.

The goal is this will provide physicians insight into the clinical characteristics, treatment strategies, and outcomes of STEMI patients with COVID-19 infection. This registry has the potential to provide critically important time-sensitive data to inform the management and treatment guidelines applicable to COVID-19 patients.

The study is expected to have up to 100 sites participating throughout the United States and Canada. The registry will collect information on COVID-19 positive patients or persons under investigation (PUI) with ST-Segment Elevation or new-onset left bundle branch block with a clinical correlate of myocardial ischemia (chest pain, dyspnea, cardiac arrest, hemodynamic instability, mechanical ventilation).

The data from these patients will be compared to an age and gender-matched control population of typical STEMI patients from the existing Midwest STEMI Consortium, which is a large (>15,000), prospective multi-center registry of consecutive STEMI patients for which MHIF is the data coordinating center. More information available at https://www.scai.org/covid-19-resources.